Table 2 Demographics and outcomes prior to and following propensity score matching
Before matching | After matching | |||||
|---|---|---|---|---|---|---|
BB(−) | BB(+) | p | BB(−) | BB(+) | p | |
(n = 953) | (n = 513) | (n = 513) | (n = 513) | |||
Patient characteristics | ||||||
Sex | 0.12 | 0.613 | ||||
Male | 756 (79.3%) | 425 (82.8%) | 418 (81.5%) | 425 (82.8%) | ||
Female | 197 (20.7%) | 88 (17.2%) | 95 (18.5%) | 88 (17.2%) | ||
Age in years, mean (SD) | 63.5 (9.8) | 67.8 (8.2) | < 0.001 | 66.9 (8.3) | 67.8 (8.2) | 0.085 |
CCI | < 0.001 | 0.468 | ||||
< = 4p | 525 (55.1%) | 158 (30.8%) | 182 (35.5%) | 158 (30.8%) | ||
5–6p | 379 (39.8%) | 271 (52.8%) | 284 (55.4%) | 271 (52.8%) | ||
> 7p | 49 (5.1%) | 84 (16.4%) | 47 (9.2%) | 84 (16.4%) | ||
ASA-classification | < 0.001 | 1.00 | ||||
ASA-1 | 432 (45.3%) | 89 (17.3%) | 89 (17.3%) | 89 (17.3%) | ||
ASA-2 | 431 (45.2%) | 304 (59.3%) | 335 (65.3%) | 304 (59.3%) | ||
ASA-3 | 89 (9.3%) | 118 (23.0%) | 88 (17.2%) | 118 (23.0%) | ||
ASA-4 | 1 (0.1%) | 2 (0.4%) | 1 (0.1%) | 2 (0.4%) | ||
Histological classification | 0.032 | 0.506 | ||||
Adenocarcinoma | 737 (77.3%) | 422 (82.3%) | 413 (80.5%) | 422 (82.3%) | ||
Squamous cell carcinoma | 216 (22.7%) | 91 (17.7%) | 100 (19.5%) | 91 (17.7%) | ||
T-classification | 0.20 | 1.00 | ||||
Tx | 81 (8.5%) | 54 (10.5%) | 49 (9.6%) | 54 (10.5%) | ||
T0 | 0 (0.0%) | 2 (0.4%) | 0 (0.0%) | 2 (0.4%) | ||
T1 | 58 (6.1%) | 40 (7.8%) | 32 (6.2%) | 40 (7.8%) | ||
T2 | 262 (27.5%) | 140 (27.3%) | 138 (26.9%) | 140 (27.3%) | ||
T3 | 514 (53.9%) | 259 (50.5%) | 276 (53.8%) | 259 (50.5%) | ||
T4 | 38 (4.0%) | 18 (3.5%) | 18 (3.5%) | 18 (3.5%) | ||
N-classification | 0.94 | 1.00 | ||||
NX | 25 (2.6%) | 15 (2.9%) | 15 (2.9%) | 15 (2.9%) | ||
N0 | 524 (55.0%) | 270 (52.6%) | 272 (53.0%) | 270 (52.6%) | ||
N1 | 330 (34.6%) | 187 (36.5%) | 187 (36.5%) | 187 (36.5%) | ||
N2 | 63 (6.6%) | 35 (6.8%) | 35 (6.8%) | 35 (6.8%) | ||
N3 | 11 (1.2%) | 6 (1.2%) | 4 (0.8%) | 6 (1.2%) | ||
M-classification | 0.64 | 1.00 | ||||
MX | 22 (2.3%) | 16 (3.1%) | 15 (2.9%) | 16 (3.1%) | ||
M0 | 911 (95.6%) | 487 (94.9%) | 485 (94.5%) | 487 (94.9%) | ||
M1 | 20 (2.1%) | 10 (1.9%) | 13 (2.5%) | 10 (1.9%) | ||
Thoracic surgical approach | 0.58 | 1.00 | ||||
Right-sided thoracotomy | 731 (76.7%) | 398 (77.6%) | 406 (79.1%) | 398 (77.6%) | ||
Thoracoscopy | 152 (15.9%) | 69 (13.5%) | 62 (12.1%) | 69 (13.5%) | ||
Other | 70 (7.4%) | 46 (9.0%) | 45 (8.5%) | 46 (9.0%) | ||
Neoadjuvant treatment | 0.050 | 1.00 | ||||
Yes | 636 (66.7%) | 316 (61.6%) | 328 (63.9%) | 316 (61.6%) | ||
No | 313 (32.8%) | 195 (38.0%) | 184 (35.9%) | 195 (38.0%) | ||
Missing | 4 (0.4%) | 2 (0.4%) | 1 (0.2%) | 2 (0.4%) | ||
Outcome—90 day Mortality | 48 (5.0%) | 34 (6.6%) | 0.25 | 31 (6.0%) | 34 (6.6%) | 0.798 |